[go: up one dir, main page]

WO2004056989A3 - Human variants of kallikrein-2 and kallikrein-3 and uses thereof - Google Patents

Human variants of kallikrein-2 and kallikrein-3 and uses thereof Download PDF

Info

Publication number
WO2004056989A3
WO2004056989A3 PCT/FR2003/003775 FR0303775W WO2004056989A3 WO 2004056989 A3 WO2004056989 A3 WO 2004056989A3 FR 0303775 W FR0303775 W FR 0303775W WO 2004056989 A3 WO2004056989 A3 WO 2004056989A3
Authority
WO
WIPO (PCT)
Prior art keywords
kallikrein
concerns
pathologies
methods
human variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/003775
Other languages
French (fr)
Other versions
WO2004056989A2 (en
Inventor
Laurent Bracco
Brigitta Brinkman
Fanny Coignard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Priority to AU2003300655A priority Critical patent/AU2003300655A1/en
Publication of WO2004056989A2 publication Critical patent/WO2004056989A2/en
Publication of WO2004056989A3 publication Critical patent/WO2004056989A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns the field of biology, genetics and medicine. It concerns in particular novel methods for detecting, characterizing and/or treating cancer pathologies, in particular prostatic cancer. The invention also concerns methods for identifying or screening compounds active in said pathologies. The invention further concerns compounds, genes, cells, plasmids or compositions useful for implementing said methods. The invention concerns in particular the role of human variants of kallikrein-2 and kallikrein-3, also referred to as PSA, in said pathologies and their uses as therapeutic, diagnostic or experimental targets.
PCT/FR2003/003775 2002-12-17 2003-12-17 Human variants of kallikrein-2 and kallikrein-3 and uses thereof Ceased WO2004056989A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003300655A AU2003300655A1 (en) 2002-12-17 2003-12-17 Human variants of kallikrein-2 and kallikrein-3 and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/16019 2002-12-17
FR0216019A FR2848569A1 (en) 2002-12-17 2002-12-17 New nucleic acid encoding variants of human kallikrein-3, useful for diagnosis of prostatic cancer and in screening for therapeutic agents, also related polypeptides and antibodies

Publications (2)

Publication Number Publication Date
WO2004056989A2 WO2004056989A2 (en) 2004-07-08
WO2004056989A3 true WO2004056989A3 (en) 2005-01-06

Family

ID=32338902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/003775 Ceased WO2004056989A2 (en) 2002-12-17 2003-12-17 Human variants of kallikrein-2 and kallikrein-3 and uses thereof

Country Status (3)

Country Link
AU (1) AU2003300655A1 (en)
FR (1) FR2848569A1 (en)
WO (1) WO2004056989A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046403A1 (en) * 1998-03-11 1999-09-16 Exonhit Therapeutics S.A. Qualitative differential screening
WO2000011015A1 (en) * 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
WO2000049158A2 (en) * 1999-02-18 2000-08-24 Compugen Ltd. Psa and klk-2 splicing variants
WO2003076610A2 (en) * 2002-03-14 2003-09-18 Exonhit Therapeutics Sa Variants of human kallikrein-2 and kallikrein-3 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2440747A1 (en) * 2001-03-15 2002-09-26 Hyseq, Inc. Novel nucleic acids and polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046403A1 (en) * 1998-03-11 1999-09-16 Exonhit Therapeutics S.A. Qualitative differential screening
WO2000011015A1 (en) * 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
WO2000049158A2 (en) * 1999-02-18 2000-08-24 Compugen Ltd. Psa and klk-2 splicing variants
WO2003076610A2 (en) * 2002-03-14 2003-09-18 Exonhit Therapeutics Sa Variants of human kallikrein-2 and kallikrein-3 and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID ANAT ET AL: "Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 20, 17 May 2002 (2002-05-17), May 17, 2002, pages 18084 - 18090, XP002241550, ISSN: 0021-9258 *
EXONHIT THERAPEUTICS: "Exonhit Therapeutics and IDEC Pharmaceuticals announce collaborative agreement in target discovery", PRESS RELEASE, 1 July 2002 (2002-07-01), XP002222065 *
SHARIAT SHAHROKH F ET AL: "Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy", CANCER RESEARCH, vol. 62, no. 20, 15 October 2002 (2002-10-15), pages 5974 - 5979, XP002290010, ISSN: 0008-5472 *
YOUSEF GEORGE M ET AL: "Human tissue kallikreins: A new enzymatic cascade pathway?", BIOLOGICAL CHEMISTRY, vol. 383, no. 7-8, July 2002 (2002-07-01), pages 1045 - 1057, XP008033390, ISSN: 1431-6730 *

Also Published As

Publication number Publication date
AU2003300655A8 (en) 2004-07-14
WO2004056989A2 (en) 2004-07-08
FR2848569A1 (en) 2004-06-18
AU2003300655A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
WO2005030121A3 (en) Compounds, compositions and methods
WO2005062881A3 (en) Gene therapy using transposon-based vectors
WO2004048551A3 (en) Target for therapy of cognitive impairment
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
TR200500221T2 (en) Bicyclic Amino Acids as Pharmaceutical Substances
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
WO2004046332A3 (en) Amplified genes involved in cancer
AU2003249645A1 (en) METHODS FOR THE IDENTIFICATION OF IKKAlpha FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
GB0418388D0 (en) Cell therapy
MXPA05010575A (en) Peptabody for cancer treatment.
AU2003245927A1 (en) Target genes for the diagnosis and treatment of cancer
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
TW200724679A (en) Treatment of disease using an improved regulated expression system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP